GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Debt-to-Revenue

Karolinska Development AB (Karolinska Development AB) Debt-to-Revenue : 1.51 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Karolinska Development AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.27 Mil. Karolinska Development AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Karolinska Development AB's annualized Revenue for the quarter that ended in Mar. 2024 was $0.18 Mil. Karolinska Development AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 1.51.


Karolinska Development AB Debt-to-Revenue Historical Data

The historical data trend for Karolinska Development AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Debt-to-Revenue Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.78 28.88 57.70 0.33 1.53

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.18 0.16 1.44 1.51

Competitive Comparison of Karolinska Development AB's Debt-to-Revenue

For the Biotechnology subindustry, Karolinska Development AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's Debt-to-Revenue falls into.



Karolinska Development AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Karolinska Development AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.299 + 0) / 0.196
=1.53

Karolinska Development AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.272 + 0) / 0.18
=1.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Karolinska Development AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (Karolinska Development AB) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.